Analytical Data
-
Gene name
TRIAP1
- Application
-
Alternative Names
Protein 15E1.1 WF-1 p53-inducible cell-survival factor
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43715
-
Expression Region
1-76aa
-
Molecular Weight
35.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRIAP1 (TP53-regulated inhibitor of apoptosis 1) is a protein that plays a crucial role in various cellular processes, particularly in apoptosis and cellular stress responses. As a member of the anti-apoptotic Bcl-2 family, TRIAP1 is known to interact with p53, a key tumor suppressor protein, thereby influencing cell survival and proliferation. Recent studies have highlighted TRIAP1's involvement in cancer biology, where its overexpression has been associated with enhanced tumor cell survival and resistance to chemotherapy, making it a potential target for cancer therapy. The study of recombinant TRIAP1 protein is significant as it allows for a better understanding of its functional mechanisms, interaction partners, and regulatory pathways. By producing TRIAP1 in a recombinant form, researchers can investigate its structural properties, perform binding assays, and elucidate its role in modulating apoptotic signals within the cell. Furthermore, the generation of monoclonal antibodies against TRIAP1 could facilitate the development of diagnostic tools or therapeutic strategies aimed at targeting TRIAP1 in tumors. As research progresses, a deeper understanding of TRIAP1's molecular functions is expected to contribute to novel cancer treatment approaches, ultimately improving patient outcomes in oncological settings.
